Applied psychopharmacotherapy and psychotherapy do not always bring the expected
results in the treatment of mental disorders. As a result, other interventions are receiving …

Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from
genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also …

Objectives: This guideline provides recommendations for the clinical management of
schizophrenia and related disorders for health professionals working in Australia and New …

Objective: Approximately 20%–35% of individuals 12–35 years old who meet criteria for a
prodromal risk syndrome convert to psychosis within 2 years. However, this estimate ignores …

The brain is highly enriched with fatty acids. These include the polyunsaturated fatty acids
(PUFAs) arachidonic acid and docosahexaenoic acid, which are largely esterified to the …

Docosahexaenoic acid (DHA) is a structural constituent of membranes specifically in the
central nervous system. Its accumulation in the fetal brain takes place mainly during the last …

Background The clinical high‐risk state for psychosis (CHR‐P) paradigm has facilitated the
implementation of psychosis prevention into clinical practice; however, advancements in …

Schizophrenia has been primarily associated with dopamine dysfunction, and treatments
have been developed that target the dopamine pathway in the central nervous system …

Context During the past 2 decades, a major transition in the clinical characterization of
psychotic disorders has occurred. The construct of a clinical high-risk (HR) state for …

A growing body of evidence has emerged demonstrating a pathological link between
oxidative stress and schizophrenia. This evidence identifies oxidative stress as a …